196 related articles for article (PubMed ID: 17768699)
1. Fixed vs random effects meta-analysis in rare event studies: the rosiglitazone link with myocardial infarction and cardiac death.
Shuster JJ; Jones LS; Salmon DA
Stat Med; 2007 Oct; 26(24):4375-85. PubMed ID: 17768699
[TBL] [Abstract][Full Text] [Related]
2. Meta-analysis of rare events: an update and sensitivity analysis of cardiovascular events in randomized trials of rosiglitazone.
Dahabreh IJ; Economopoulos K
Clin Trials; 2008; 5(2):116-20. PubMed ID: 18375649
[TBL] [Abstract][Full Text] [Related]
3. Comments on 'Fixed vs random effects meta-analysis in rare event studies: the rosiglitazone link with myocardial infarction and cardiac death'.
Carpenter J; Rücker G; Schwarzer G
Stat Med; 2008 Aug; 27(19):3910-2; author reply 3912-4. PubMed ID: 18069734
[No Abstract] [Full Text] [Related]
4. Cardiac safety profile of rosiglitazone: a comprehensive meta-analysis of randomized clinical trials.
Mannucci E; Monami M; Di Bari M; Lamanna C; Gori F; Gensini GF; Marchionni N
Int J Cardiol; 2010 Aug; 143(2):135-40. PubMed ID: 19328563
[TBL] [Abstract][Full Text] [Related]
5. Pioglitazone and the risk of myocardial infarction and other major adverse cardiac events: a meta-analysis of randomized, controlled trials.
Nagajothi N; Adigopula S; Balamuthusamy S; Velazquez-Cecena JL; Raghunathan K; Khraisat A; Singh S; Molnar J; Khosla S; Benatar D
Am J Ther; 2008; 15(6):506-11. PubMed ID: 19127132
[TBL] [Abstract][Full Text] [Related]
6. Meta-analysis of incidence of rare events.
Lane PW
Stat Methods Med Res; 2013 Apr; 22(2):117-32. PubMed ID: 22218366
[TBL] [Abstract][Full Text] [Related]
7. Challenges in meta-analysis of randomized clinical trials for rare harmful cardiovascular events: the case of rosiglitazone.
Hernandez AV; Walker E; Ioannidis JP; Kattan MW
Am Heart J; 2008 Jul; 156(1):23-30. PubMed ID: 18585493
[TBL] [Abstract][Full Text] [Related]
8. Analytical issues regarding rosiglitazone meta-analysis.
Claggett B; Wei LJ
Arch Intern Med; 2011 Jan; 171(2):179-80; author reply 180. PubMed ID: 21263111
[No Abstract] [Full Text] [Related]
9. Thiazolidinediones in type 2 diabetes: a cardiology perspective.
Khanderia U; Pop-Busui R; Eagle KA
Ann Pharmacother; 2008 Oct; 42(10):1466-74. PubMed ID: 18698014
[TBL] [Abstract][Full Text] [Related]
10. The rough road for rosiglitazone.
Goldfine AB
Curr Opin Endocrinol Diabetes Obes; 2008 Apr; 15(2):113-7. PubMed ID: 18316944
[TBL] [Abstract][Full Text] [Related]
11. What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data.
Sweeting MJ; Sutton AJ; Lambert PC
Stat Med; 2004 May; 23(9):1351-75. PubMed ID: 15116347
[TBL] [Abstract][Full Text] [Related]
12. Comments on 'Rebuttal to Carpenter et al.' Comments on 'Fixed vs random effects meta-analysis in rare event studies: the rosiglitazone link with myocardial infarction and cardiac death' by J. J. Shuster, L. S. Jones and D. A. Salmon, Statistics in Medicine 2008; 27:3912-3914.
Waksman J; Kollar C
Stat Med; 2009 Feb; 28(3):534-6. PubMed ID: 19125393
[No Abstract] [Full Text] [Related]
13. The rosiglitazone meta-analysis.
McCullough PA; Lepor NE
Rev Cardiovasc Med; 2007; 8(2):123-6. PubMed ID: 17603430
[No Abstract] [Full Text] [Related]
14. Why should we avoid the use of rosiglitazone?
Mikhail N
South Med J; 2008 Mar; 101(3):329-31. PubMed ID: 18364671
[No Abstract] [Full Text] [Related]
15. Rosiglitazone and myocardial infarction: cause for concern or misleading meta-analysis?
Bilous RW
Diabet Med; 2007 Sep; 24(9):931-3. PubMed ID: 17725705
[No Abstract] [Full Text] [Related]
16. Faster publication isn't always better.
Fuster V; Farkouh ME
Nat Clin Pract Cardiovasc Med; 2007 Jul; 4(7):345. PubMed ID: 17589426
[No Abstract] [Full Text] [Related]
17. [Statistical analysis of community-based studies -- presentation and comparison of possible solutions with reference to statistical meta-analytic methods].
Twardella D; Bruckner T; Blettner M
Gesundheitswesen; 2005 Jan; 67(1):48-55. PubMed ID: 15672306
[TBL] [Abstract][Full Text] [Related]
18. Evaluating the benefit of event adjudication of cardiovascular outcomes in large simple RCTs.
Pogue J; Walter SD; Yusuf S
Clin Trials; 2009 Jun; 6(3):239-51. PubMed ID: 19528133
[TBL] [Abstract][Full Text] [Related]
19. Was there really any evidence that rosiglitazone increased the risk of myocardial infarction or death from cardiovascular causes?
Stone JC; Furuya-Kanamori L; Barendregt JJ; Doi SA
Pharmacoepidemiol Drug Saf; 2015 Mar; 24(3):223-7. PubMed ID: 25515780
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular risk of rosiglitazone: another perspective.
Waksman JC
J Pharm Pharmacol; 2008 Dec; 60(12):1573-82. PubMed ID: 19000361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
